The FDA has approved tirzepatide – which will be sold under the brand name Zepbound – to treat overweight and obesity. It’s the latest entrant into a field of powerful new drugs that includes Ozempic and Wegovy.
A dual-chamber wireless pacemaker provides reliable performance over three months, bolstering evidence for this new option, according to results from a multi-center international clinical trial co-led by a Weill Cornell Medicine investigator.
A study identifies microbes that potentially play important roles in breaking down harmful PFAS chemicals and points to functional genes that may be involved.
TeraPore Technologies, co-founded by Rachel Dorin, Ph.D. ’13, and its novel nanofiltration products are changing how the pharmaceutical industry is reducing risk of harmful virus contamination in biological drugs.
Nutritionists generally advise everyone to eat more dietary fiber, but a new study suggests that its effects on health can vary, suggesting that recommendations should be tailored to each individual’s gut microbiome.
Intimate partner violence is notoriously underreported and correctly diagnosed at hospitals only around a quarter of the time, but a new method provides a more realistic picture of which groups of women are most affected, even when their cases go unrecorded.
Ashley Nelson, assistant professor of immunology research in the Department of Pediatrics at Weill Cornell Medicine, has received a 2023 Hartwell Individual Biomedical Research Award from The Hartwell Foundation.
The fireside chat was part of a two-day visit by Dr. Robert M. Califf, commissioner of the U.S. Food and Drug Administration, who focused on medicine and health care innovations.
